Skip to main content
ConsultationsConsultations Archive

CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

By April 10, 2024No Comments

The National Institute for Health and Care Excellence (NICE) is producing guidance on using clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack in the NHS in England. The diagnostics advisory committee has considered the evidence and the views of clinical and patient experts.

This document has been prepared for public consultation. It summarises the evidence and views that have been considered, and sets out the recommendations made by the committee. NICE invites comments from registered stakeholders, healthcare professionals and the public. This document should be read along with the evidence (the external assessment report and the external assessment report erratum).

The advisory committee is interested in receiving comments on the following:

  • Has all of the relevant evidence been taken into account?
  • Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
  • Are the recommendations sound, and a suitable basis for guidance to the NHS?

You can now comment on the diagnostics consultation document 

 It summarises the evidence and views that have been considered and sets out the recommendations made by the committee. NICE invites comments from registered stakeholders, healthcare professionals and the public.  

Closing date for comments: 26 April 2024

Ben Kemp